BRTX Biorestorative Therapies
- 1.530
- +0.050+3.37%
Biorestorative Therapies News
Maxim Group Maintains Biorestorative Therapies(BRTX.US) With Buy Rating, Maintains Target Price $6
Positive Outlook for BioRestorative Therapies: Phase 2 Trial Results Drive Buy Rating
Roth MKM Remains a Buy on BioRestorative Therapies (BRTX)
BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript Summary
BioRestorative Therapies Showcases Promising Stem Cell Advances
Biorestorative Therapies | 8-K: BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
BioRestorative Therapies GAAP EPS of -$0.13 Beats by $0.30
BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function
Express News | BioRestorative Therapies Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Revenue Results. Additionally, the Company Reported Preliminary Phase 2 BRTX-100 Clinical Data Showing a Material Decrease in Pain and Increased Function
Express News | BioRestorative Therapies Inc - Patient Reported Efficacy Outcomes Show a Material Decrease in Pain and Increase in Function
Biorestorative Therapies | 10-Q: Q3 2024 Earnings Report
BioRestorative Therapies 3Q Loss/Shr 13c >BRTX
Express News | BioRestorative Therapies Q3 Operating Income USD -2.3 Million
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
Earnings Preview: BRTX to Report Financial Results Post-market on November 13
BioRestorative Therapies to Announce Phase 2 Trial Data
BioRestorative Therapies Ends Agreement With JonesTrading
Biorestorative Therapies | 10-K/A: Annual report (Amendment)
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
BioRestorative Therapies Receives Expanded Tissue License From New York State Department of Health
Analysis
Price Target
No Data
No Data